MX2016005867A - Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano. - Google Patents

Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.

Info

Publication number
MX2016005867A
MX2016005867A MX2016005867A MX2016005867A MX2016005867A MX 2016005867 A MX2016005867 A MX 2016005867A MX 2016005867 A MX2016005867 A MX 2016005867A MX 2016005867 A MX2016005867 A MX 2016005867A MX 2016005867 A MX2016005867 A MX 2016005867A
Authority
MX
Mexico
Prior art keywords
dextromethorphan
compositions
bupropion
methods
related compounds
Prior art date
Application number
MX2016005867A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of MX2016005867A publication Critical patent/MX2016005867A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

En esta divulgación se describe un método para tratar un trastorno neurológico mediante la administración de un compuesto antidepresivo y dextrometorfano a un ser humano que lo necesita. Este método puede ser útil para seres humanos, los cuales son metabolizadores extensos de dextrometorfano. También se describen composiciones, medicamentos y formas de dosificación que comprenden compuestos antidepresivos y dextrometorfano.
MX2016005867A 2013-11-05 2014-11-05 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano. MX2016005867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900354P 2013-11-05 2013-11-05
PCT/US2014/064184 WO2015069809A1 (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan

Publications (1)

Publication Number Publication Date
MX2016005867A true MX2016005867A (es) 2016-07-15

Family

ID=53042051

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016005867A MX2016005867A (es) 2013-11-05 2014-11-05 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
MX2020004075A MX2020004075A (es) 2013-11-05 2014-11-05 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
MX2021015234A MX2021015234A (es) 2013-11-05 2016-05-04 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020004075A MX2020004075A (es) 2013-11-05 2014-11-05 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
MX2021015234A MX2021015234A (es) 2013-11-05 2016-05-04 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.

Country Status (12)

Country Link
EP (3) EP3981404A1 (es)
JP (4) JP6605485B2 (es)
KR (4) KR102264179B1 (es)
CN (7) CN113750098A (es)
AU (6) AU2014346807B2 (es)
CA (3) CA3175703A1 (es)
IL (3) IL298972A (es)
MX (3) MX2016005867A (es)
MY (1) MY179696A (es)
NZ (5) NZ758425A (es)
SG (4) SG11201603391XA (es)
WO (1) WO2015069809A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
KR102264179B1 (ko) * 2013-11-05 2021-06-11 안테씨프 바이오벤쳐스 투 엘엘씨 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
TW202231278A (zh) * 2014-09-14 2022-08-16 美商阿瓦尼爾製藥股份有限公司 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物
CN111297860A (zh) 2014-11-21 2020-06-19 安泰赛普生物风投二代有限责任公司 使用赤式羟基安非他酮调节药物血浆水平的方法
EP3432885A4 (en) * 2016-03-24 2019-11-20 Antecip Bioventures II LLC COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFE OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
MX2021008247A (es) * 2019-01-07 2021-08-16 Antecip Bioventures Ii Llc Combinacion de dextrometorfano y bupropion para el tratamiento de depresion.
EP4125837A4 (en) * 2020-03-30 2024-03-20 Antecip Bioventures Ii Llc USE OF BUPROPION AND DEXTROMETHORPHANE COMBINATIONS TO TREAT NEUROLOGICAL DISEASES
TW202206075A (zh) * 2020-07-20 2022-02-16 大陸商深圳信立泰藥業股份有限公司 一種藥物組合物及其應用
EP4255433A1 (en) 2020-12-01 2023-10-11 Antecip Bioventures II LLC Bupropion and dextromethrophan for reduction of suicide risk in depression patients
KR20230131927A (ko) * 2021-01-18 2023-09-14 안테씨프 바이오벤쳐스 투 엘엘씨 신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합
CN112999350A (zh) * 2021-02-23 2021-06-22 北京斯利安药业有限公司 一种药物组合物、复方制剂及其制备方法与应用
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
CA2289190A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
MX2008009947A (es) * 2006-02-03 2008-10-20 Avanir Pharmaceuticals Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
WO2009006194A1 (en) * 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
KR102264179B1 (ko) * 2013-11-05 2021-06-11 안테씨프 바이오벤쳐스 투 엘엘씨 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Also Published As

Publication number Publication date
IL245504B (en) 2021-06-30
AU2019236614B2 (en) 2021-07-15
IL245504A0 (en) 2016-06-30
WO2015069809A1 (en) 2015-05-14
KR20220054909A (ko) 2022-05-03
AU2018203638A1 (en) 2018-06-14
CA2929415A1 (en) 2015-05-14
NZ758425A (en) 2021-07-30
AU2014346807B2 (en) 2018-03-22
NZ758428A (en) 2021-07-30
AU2019236614A1 (en) 2019-10-17
SG11201603391XA (en) 2016-05-30
JP6927601B2 (ja) 2021-09-01
SG10201911808QA (en) 2020-01-30
JP2023129646A (ja) 2023-09-14
EP3065742A1 (en) 2016-09-14
CA3154845A1 (en) 2015-05-14
KR20230148385A (ko) 2023-10-24
AU2019236614C1 (en) 2021-10-14
NZ758431A (en) 2021-07-30
EP3981404A1 (en) 2022-04-13
CA2929415C (en) 2023-01-03
AU2019275593A1 (en) 2020-01-02
NZ719892A (en) 2021-07-30
KR20210068157A (ko) 2021-06-08
CN110279682A (zh) 2019-09-27
AU2023203438A1 (en) 2023-07-06
IL283760A (en) 2021-07-29
CN113750098A (zh) 2021-12-07
KR20160070158A (ko) 2016-06-17
JP2016535786A (ja) 2016-11-17
CN110251517A (zh) 2019-09-20
MX2020004075A (es) 2021-12-10
MY179696A (en) 2020-11-11
JP2021169527A (ja) 2021-10-28
NZ758432A (en) 2021-07-30
SG10201911816XA (en) 2020-01-30
AU2021202497A1 (en) 2021-05-27
EP3065742A4 (en) 2017-04-05
KR102264179B1 (ko) 2021-06-11
AU2018203638B2 (en) 2019-07-18
JP2020023543A (ja) 2020-02-13
IL283760B2 (en) 2023-05-01
AU2019275593B2 (en) 2021-01-28
JP6605485B2 (ja) 2019-11-13
CA3154845C (en) 2023-02-28
IL298972A (en) 2023-02-01
SG10201810888XA (en) 2019-01-30
CN106163522A (zh) 2016-11-23
CN110327338A (zh) 2019-10-15
KR102603013B1 (ko) 2023-11-15
AU2018203638C1 (en) 2019-10-24
MX2021015234A (es) 2022-05-26
CN113797205A (zh) 2021-12-17
AU2021202497B2 (en) 2023-03-02
EP3981403A1 (en) 2022-04-13
AU2014346807A1 (en) 2016-05-19
CA3175703A1 (en) 2015-05-14
IL283760B1 (en) 2023-01-01
CN113750099A (zh) 2021-12-07

Similar Documents

Publication Publication Date Title
MX2021015234A (es) Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2015004362A (es) Derivados de ketamina.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
NZ722600A (en) Methods of treating mild brain injury
MX2022015141A (es) Composiciones y metodos de uso de un compuesto de control de inapetencia.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
EA033769B9 (ru) Отселектированный амид -гидроксимасляной кислоты и его применения при лечении злоупотребления алкоголем
GB2515440A (en) Vesicular formulations
EA201690446A1 (ru) Лечение множественной миеломы
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
UA113859C2 (xx) Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем
MX2016002307A (es) Tratamiento para el cancer.
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
IN2013MU03428A (es)
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.

Legal Events

Date Code Title Description
FG Grant or registration